This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Non-Hodgkin lymphoma
  • /
  • Guidelines for the investigation and management of...

Guidelines for the investigation and management of mantle cell lymphoma

Read time: 1 mins
Last updated:1st Nov 2012

Mantle cell lymphoma (MCL) is a B-cell malignancy with unique biological, pathological and clinical features, which comprises approximately 3–10% of all non-Hodgkin lymphomas (NHLs) (Swerdlow et al, 2008).  

This guideline discusses the investigation and management of patients with mantle cell lymphoma including diagnosis.

Prognostic scores: First line management with emphasis on the different approach for younger, fitter (transplant candidate) patients and watch and wait option for those with asymptomatic, indolent disease.

The section on diagnosis of mantle cell lymphoma, should be considered supplementary to the BSH Guideline: Best Practice in Lymphoma Diagnosis and Reporting (Parker et al, 2010).


Read full guideline